In primary ovarian insufficiency, estrogen replacement is used to protect bones, heart health, and quality of life while the woman would have been naturally menopausal. The duration of therapy is therefore aligned with the time until the age at which menopause would normally occur. That point is the average age of natural menopause, which is about 50–51 years. So continuing hormone therapy until that average age makes sense: it covers the years of low estrogen and then can be reassessed as menopause would begin in most women around that time. Choosing a fixed age like 60 would extend therapy longer than typical need and may unnecessarily increase long-term risks. Taking it for life ignores the natural transition that happens around menopause. While age 50 is close to the average, stating it as the exact end point ignores the population-wide variation around the average. The phrasing “the average age of menopause” best captures the intended endpoint for therapy duration in POI.

Routine DXA screening for osteoporosis in postmenopausal women begins at age 65. The guideline allows for earlier, selective screening in women aged 50–64 if there are additional fracture risk factors such as a prior fragility fracture, long-term glucocorticoid use, low BMI, smoking, or a family history of hip fracture. This approach aims to identify those at higher risk while avoiding routine screening in lower-risk younger postmenopausal women. Ages 50 or 60 fall below the routine threshold, while 70 would be screened routinely because it is above 65.

Treating osteoporosis centers on drugs that slow bone loss by inhibiting bone resorption. Bisphosphonates are the most commonly used and typically first-line therapy. They attach to bone and suppress osteoclast activity, reducing bone turnover and helping to increase or stabilize bone mineral density, which lowers the risk of fractures. Examples include alendronate, risedronate, ibandronate, and zoledronic acid, given orally on a weekly/monthly schedule or by yearly IV infusion. Other drug classes listed serve different roles. ACE inhibitors treat high blood pressure and heart failure, not osteoporosis. Thiazolidinediones are diabetes medications that can actually worsen bone density and fracture risk. Statins lower cholesterol and have unclear or limited evidence for a role in treating osteoporosis, so they are not standard osteoporosis therapies.

During perimenopause, the ovaries become erratic and estrogen levels fluctuate, so ovulatory cycles become unpredictable and the endometrium sheds irregularly. This leads to irregular bleeding in both timing and flow. At the same time, instability in the hypothalamic–pituitary–ovarian axis and estrogen withdrawal produce vasomotor symptoms such as hot flashes and night sweats. The combination of irregular bleeding with vasomotor symptoms best reflects LOOP events in this phase, because it ties together the endometrial instability with the central temperature-regulation changes typical of this transition. Regular bleeding with steady vasomotor symptoms suggests more stable cycling, heavy bleeding without vasomotor symptoms is less typical for the common perimenopausal pattern, and no bleeding with no symptoms points away from the perimenopausal experience.